Pharmaids Pharmaceuticals Limited has scheduled its 37th Annual General Meeting (AGM) for September 11, 2026, to approve its financial results for FY26. The company posted a significant increase in top-line growth alongside a widening bottom-line loss, driven by higher operational costs and finance expenses.

On a standalone basis, revenue from operations surged 353% to ₹106.0 crore from ₹23.4 crore in FY25. However, this growth was offset by a rise in total expenses to ₹283.3 crore from ₹119.5 crore, resulting in a net loss of ₹104.4 crore compared to ₹72.8 crore previously. Consolidated revenue rose 43% to ₹278.8 crore from ₹194.5 crore, while the consolidated net loss narrowed slightly to ₹115.7 crore from ₹135.1 crore.

Key Financial Metrics

Strategic Disinvestments and Related Party Transactions

During FY26, Pharmaids executed several material transactions to restructure its portfolio. The company disinvested its entire 66.50% partnership interest in Anugraha Chemicals for an overall value of ₹102.4 crore, comprising consideration for the stake and settlement of dues. Additionally, Adita Bio Sys Private Limited, a material subsidiary, ceased holding a step-down subsidiary, Siri Labvivo Diet Private Limited, following a share transfer to an unrelated party.

In a related party transaction, the company sold three land parcels in Tumkur to Dr. S. N. Vinaya Babu, then Chairman and now Vice-Chairman, for ₹19.4 crore. The transaction was approved by shareholders via postal ballot and determined on an arm’s-length basis. The Board also recommended no dividend for the year.

What the Numbers Show

The divergence between standalone and consolidated performance highlights the operational weight of its subsidiaries. While the standalone entity saw revenue triple, it incurred a gross operating loss as expenses nearly tripled relative to the prior year. Conversely, the consolidated group showed more moderate revenue growth but managed to reduce the absolute net loss, suggesting that subsidiary operations, despite their own challenges, provided some stabilizing effect on the group's overall bottom line compared to the parent company's standalone trajectory.

Pharmaids Pharmaceuticals Limited has appointed M/s. V Mahendra & Associates Chartered Accountants as its internal auditor for the financial year 2026-27. The Board of Directors approved the appointment on June 30, 2026, following the recommendation of the Audit Committee. The firm will oversee internal audit functions to ensure compliance and strengthen internal controls.

The appointment was disclosed to BSE Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that the information is available on its website. The decision aligns with the requirements of SEBI Master Circular dated January 30, 2026.

M/s. V Mahendra & Associates is a Chartered Accountant firm with over 23 years of professional experience. The firm specializes in assisting corporate entities with statutory compliance, internal controls, financial reporting systems, and operational efficiency. Its registration number is 025356S.

The table below outlines the key details of the appointment:

The disclosure was signed by Prasanna Subramanya Bhat, Company Secretary & Compliance Officer of Pharmaids Pharmaceuticals Limited . The appointment is effective immediately for the specified financial year.